Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

Share Price is delayed by 15 minutes
Get Live Data
66.50    0.00 (0.00%)
Bid:
65.00
Ask:
68.00
Spread: 3.00 (4.615%)
Market Cap: £16.20m
MYX Live PriceLast checked at - London Stock Exchange

Intraday Mycelx Di Share Chart

Trading Update

2 Mar 2021 07:00

RNS Number : 7803Q
MyCelx Technologies Corporation
02 March 2021
 

2 March 2021

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). This inside information is now considered to be in the public domain.

 

 

MYCELX TECHNOLOGIES CORPORATION (AIM: MYX)

 

Trading Update

 

MYCELX Technologies Corporation ("MYCELX" or the "Company"), the clean water and air technology experts, supplying customers with cost-effective, future-proof solutions that optimise production and protect the environment, is pleased to announce a trading update on the Company's operations.

 

MYCELX has made a strong start to the year with two project extensions signed with customers in the Kingdom of Saudi Arabia. These projects confirm that MYCELX's superior solutions continue to support its customers' efforts to optimise production, increase cost savings and improve energy efficiency. During Q1, the Company will commence delivery of the equipment for its third sale to Nigeria.

 

Following product development initiatives in 2020, carried out to enhance its REGEN solution, the Company has secured a paid trial. This will demonstrate REGEN's superior performance over other water treatment offerings for Enhanced Oil Recovery ("EOR") production. The Company has commenced fabrication of this system in Q1 and anticipates that a successful outcome of this trial will lead to heightened interest in the REGEN product offering by leading EOR producers.

 

The value of these project extensions, trial and capital sale amounts to $3.5m in revenue for 2021.

 

As previously reported, the impact of the COVID-19 pandemic and the resulting disruption to its core markets meant that 2020 was an extremely challenging year for the business, with generated revenue of $7.1 million during the year. The Company's strong start to this year demonstrates it has successfully navigated the downturn by focusing on supporting customers, advancing product development initiatives and implementing cost controls. The Company notes the recent increase in activity in core markets, and is well positioned to progress new contracts as the global economy begins to recover.

 

MYCELX also recently announced the sale of its building in Duluth, Georgia, USA, to right-size its office space needs across its main operating locations, as part of the cost reduction program. The sale enables MYCELX to achieve a financial gain of approximately $2.5 million. After the sale closes, the Company will have circa $6 million of cash and cash equivalents on the balance sheet.

 

Commenting on the market update, Connie Mixon, CEO, said:

 

"Following a challenging year, I am pleased to report that we are seeing an increase in activity in the markets in which we operate. This can be seen with the two contract extensions we have signed in Q1 2021, alongside the exciting opportunities arising from the paid trial for REGEN and our development of novel product applications. While we expect it to take time for the wider energy and industrial markets to normalize, we anticipate bidding activity by customers to increase, bolstered by the global economic recovery.

 

The Company continues to benefit from being in a financially robust position, following the cost reduction measures implemented in 2020 and the sale of the building in Duluth, and we look forward to keeping our stakeholders updated on our business progress over the coming months."

 

 

For further information please contact: 

 

MYCELX Technologies Corporation

Connie Mixon, CEO

Kim Slayton, CFO

 

 

 

Tel: +1 888 306 6843

Canaccord Genuity, Nominated Adviser

Henry Fitzgerald-O'Connor

Georgina McCooke

 

 

Tel: + 44 20 7523 8000

Celicourt

Mark Antelme

Jimmy Lea

 

Tel: +44 20 8434 2754

 

 

Notes to Editors

MYCELX is a revolutionary oil-free water technology company solving the world's toughest oil removal problems in the Oil and Gas industry. The systems are based upon scientific breakthrough for a completely different approach to permanent oil removal. The Company created the patented MYCELX polymer using innovative molecular cohesion for removing oil from water far beyond what conventional systems have ever achieved. MYCELX systems remove oil to critically low levels in a much smaller physical footprint than conventional systems and in a virtually fail-safe process.

www.mycelx.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSSUEFFEFSEED
Date   Source Headline
22nd Feb 20247:00 amRNSSaudi Arabia Business Operation Sale
21st Nov 20237:00 amRNSContract Update
16th Nov 20237:00 amRNSTrading Update
26th Sep 20233:10 pmRNSResult of Annual Meeting
20th Sep 20237:00 amRNSHalf Year Results Statement
11th Jul 20237:00 amRNSContract Award
5th Jul 20233:28 pmRNSHolding(s) in Company
3rd Jul 20232:37 pmRNSContract Award & PFAS Update
21st Jun 20237:00 amRNSMailing of AR and Notice of 2023 Annual Meeting
18th May 20237:00 amRNSFinal Results for the Year Ending 31 December 2022
12th May 20237:00 amRNSHolding(s) in Company
17th Apr 20237:00 amRNSSuccessful leach testing of PFAS media
14th Mar 20234:50 pmRNSClosure of Restricted Stock Line
8th Mar 20237:00 amRNSPilot Testing Agreement for PFAS Remediation
13th Feb 20237:00 amRNSOperational Update
31st Jan 20237:00 amRNSTrading Update
24th Jan 20237:00 amRNSContract Secured for PFAS Remediation System
8th Dec 20227:00 amRNSTrading Update
27th Sep 20227:00 amRNSHalf Year Results Statement
15th Sep 20227:00 amRNSTrading Update
6th Sep 20222:30 pmRNSHolding(s) in Company
30th Aug 20227:00 amRNSNew Project Awards and Operations Update
13th Jul 20223:32 pmRNSResult of Annual Meeting
13th Jun 20227:00 amRNS2021 Annual Report & Notice of 2022 Annual Meeting
17th May 20227:00 amRNSFinal Results for Year Ending 31 December 2021
3rd May 20227:00 amRNSDirector/PDMR Shareholding
3rd May 20227:00 amRNSChange of Main Office Address
23rd Mar 20229:17 amRNSTR1
21st Mar 20225:56 pmRNSBroker Option
16th Mar 20224:09 pmRNSHolding(s) in Company
11th Mar 20221:10 pmRNSDealings by Directors
11th Mar 20227:00 amRNSProposed Placing and Subscription
11th Feb 20227:00 amRNSTrading Update
2nd Feb 202211:07 amRNSHolding(s) in Company
25th Jan 20227:00 amRNSSuccessful Trial of PFAS Remediation System
10th Jan 20227:00 amRNSAward of Green Economy Mark
23rd Nov 20212:36 pmRNSHolding(s) in Company
11th Nov 202111:51 amRNSDealings by Directors
9th Nov 20214:42 pmRNSDirector/PDMR Shareholding
5th Nov 20217:00 amRNSDirector/PDMR Shareholding
28th Oct 20214:34 pmRNSHolding(s) in Company
14th Oct 20217:00 amRNSMiddle East Contract Win
29th Sep 20217:00 amRNSHalf Year Results Statement
31st Aug 20217:00 amRNSNotice of Interim Results & Investor Presentation
11th Aug 20217:00 amRNSHolding(s) in Company
4th Aug 20217:00 amRNSContract Award and Contract Extension
7th Jul 20215:41 pmRNSResult of AGM
4th Jun 20218:00 amRNSMailing of Annual Financial Report and AM Notice
26th May 20217:00 amRNSFinal Results for the year ending 31 December 2020
19th May 20217:00 amRNSInvestor Presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.